je.st
news
Tag: trial
Ariad Pharma Discontinues Phase III Trial of Ponatinib (Iclusig) in Leukemia Patients
2013-10-20 13:07:47| Biotech - Topix.net
Ariad Pharmaceuticals, Inc. has announced that it is discontinuing the phase III EPIC trial of ponatinib in patients with newly diagnosed chronic myeloid leukemia .
Tags: iii
trial
phase
patients
Free broadband via gaps in spectrum gets biggest trial
2013-10-17 10:28:32| Wireless - Topix.net
The first mass trials of white-space wireless technology in Europe are giving the much-hyped idea a chance of breaking out into the real world WHITE space radio is not exactly in the last chance saloon, but it is close.
Tags: free
trial
biggest
spectrum
UPDATE 1-Regeneron, Sanofi drug slashes cholesterol in late-stage trial
2013-10-16 10:56:26| Biotech - Topix.net
A new type of cholesterol drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA, when used by itself, cut levels of "bad" LDL cholesterol almost in half in the first of a dozen late-stage trials of the injectable medicine.
Tags: update
trial
drug
cholesterol
Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology
2013-10-14 23:02:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind. Merck and Endocytes Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. Language: English Contact: MerckMedia:Caroline Lappetito,267-305-7639Caroline.Lappetito@Merck.comorClaire Mulhearn, 908-423-7425Claire.Mulhearn@Merck.comorInvestors:Carol Ferguson, 908-423-4465Carol.Ferguson@Merck.comorJustin Holko, 908-423-5088Justin_Holko@Merck.comorEndocyteMedia:Tony Russo, 212-845-4251Tony.Russo@Russopartnersllc.comorMartina Schwarzkopf, 212-845-4292Martina.Schwarzkopf@Russopartnersllc.comorInvestors:Stephanie Ascher, 212-362-1200Stephanie@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more
Tags: of
results
journal
published
Toyota wins unintended acceleration bellwether trial
2013-10-11 04:30:19| Green Car Congress
Tags: trial
toyota
wins
acceleration
Sites : [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] next »